To assess the safety of Opicapone in our cohort of patients with Parkinson´s disease (PD) and to clarify the efficacy of the aforementioned medication in this population.

Opicapone is a potent, third-generation, long-acting, peripheral COMT inhibitor that has been approved as adjunctive therapy to L-Dopa therapy in adults with PD and end-of-dose motor fluctuations who cannot be stabilized on those combinations. It has a favourable pharmacological profile that permits once daily administration and minimizes its potential to be associated with hepatotoxicity.

We retrospectively analyzed our PD patients who were treated with Opicapone. We collected a total of 17 patients and focused on motor/non-motor symptoms improvement and tolerance/side effects related to the drug.

18 patients were included, 10 males and 8 females. The mean age of the patients was 68.77±6.95 years and mean disease duration was 8.77±4.96 years. 15 patients had motor fluctuations and 12 patients (86.6%) had freezing of gait. The median score in the Hoehn and Yahr scale was 3.

Medication was, overall, well tolerated. 14 patients (86.6%) followed the treatment without showing any side effects and, only 4 patients (23.3%) had to discontinue the treatment (1 due to hallucinations and worsening of orthostatic hypotension and the rest due to gastrointestinal issues).

All patients showed an improvement of their motor symptoms: 9 patients described an improvement of the freezing of gate and 14 patients an improvement of motor fluctuations.

Although levodopa add-on medications in the elderly PD population should be used with caution, in our experience, Opicapone was overall well tolerated by our patients and indeed, it provided a good response over symptoms that are often considered levodopa-resistant such as freezing of gait.